Ajinomoto To Increase Pharmaceutical Business To ¥100 Billion In 2015
This article was originally published in PharmAsia News
Ajinomoto Jan. 29 announced a business plan to increase its pharmaceutical business from ¥15 billion in 2009 to ¥100 billion in 2015
You may also be interested in...
The US FDA’s Circulatory System Devices advisory panel will meet on 27 October to discuss the review of the premarket approval application of Neovasc’s Reducer device, which is intended to treat angina. See what Neovasc’s CEO Fred Colen said about it here.
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.
Appropriators’ FDA FY 2021 budget includes amendment to expand its mandatory recall authority introduced by chairman of subcommittee with oversight of agency’s budget, Rep. Sanford Bishop. He said the agency should be able to force drug product recalls as it already can for vaccines, medical devices and products containing ingredients also scheduled as controlled substances.